Diabetes - Wiki-Pi

Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide
DAB1 and ERBB3	Dab, reelin signal transducer, homolog 1 (Drosophila)	erb-b2 receptor tyrosine kinase 3
DAXX and TCF7L2	death-domain associated protein	transcription factor 7-like 2 (T-cell specific, HMG-box)		APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated S37 mutants of beta-catenin aren't phosphorylated Peptide hormone metabolism Degradation of beta-catenin by the destruction complex S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN Incretin synthesis, secretion, and inactivation truncations of AMER1 destabilize the destruction complex misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
DDIT3 and BACH2	DNA-damage-inducible transcript 3	BTB and CNC homology 1, basic leucine zipper transcription factor 2	ATF4 activates genes PERK regulates gene expression ATF6-alpha activates chaperones ATF6-alpha activates chaperone genes Unfolded Protein Response (UPR)
DTX1 and NOTCH2	deltex 1, E3 ubiquitin ligase	notch 2	Signaling by NOTCH1 HD Domain Mutants in Cancer Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Activated NOTCH1 Transmits Signal to the Nucleus Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer Signaling by NOTCH Signaling by NOTCH1 Signaling by NOTCH1 PEST Domain Mutants in Cancer Signaling by NOTCH1 in Cancer FBXW7 Mutants and NOTCH1 in Cancer	Notch-HLH transcription pathway Signaling by NOTCH2 Generic Transcription Pathway Pre-NOTCH Processing in Golgi Pre-NOTCH Transcription and Translation Signaling by NOTCH Pre-NOTCH Processing in the Endoplasmic Reticulum Pre-NOTCH Expression and Processing NOTCH2 intracellular domain regulates transcription NOTCH2 Activation and Transmission of Signal to the Nucleus
EGF and ERBB3	epidermal growth factor	erb-b2 receptor tyrosine kinase 3	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease PIP3 activates AKT signaling Platelet degranulation Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling Signaling by SCF-KIT SHC1 events in ERBB2 signaling Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants GRB2 events in ERBB2 signaling PI-3K cascade PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Response to elevated platelet cytosolic Ca2+ Innate Immune System Signaling by PDGF EGFR downregulation Signalling by NGF DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by FGFR EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR SHC1 events in EGFR signaling Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Constitutive Signaling by EGFRvIII Platelet activation, signaling and aggregation Adaptive Immune System		Sucralfate Alpha-Aminobutyric Acid
EGFR and ERBB3	epidermal growth factor receptor	erb-b2 receptor tyrosine kinase 3	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII		Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and PTPN2	epidermal growth factor receptor	protein tyrosine phosphatase, non-receptor type 2	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII		Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and SH2B3	epidermal growth factor receptor	SH2B adaptor protein 3	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by SCF-KIT Regulation of KIT signaling Factors involved in megakaryocyte development and platelet production	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGR1 and ERBB3	early growth response 1	erb-b2 receptor tyrosine kinase 3	Interferon Signaling Cytokine Signaling in Immune system Interferon alpha/beta signaling
EP300 and HNF1A	E1A binding protein p300	HNF1 homeobox A	Signaling by NOTCH1 HD Domain Mutants in Cancer Metabolism of lipids and lipoproteins Signaling by Wnt NOTCH2 intracellular domain regulates transcription Regulation of gene expression by Hypoxia-inducible Factor Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Signaling by NOTCH2 Pre-NOTCH Transcription and Translation RNF mutants show enhanced WNT signaling and proliferation Signaling by NOTCH1 in Cancer Chromatin organization misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Signaling by NOTCH formation of the beta-catenin:TCF transactivating complex Factors involved in megakaryocyte development and platelet production Chromatin modifying enzymes LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Signaling by NOTCH1 PEST Domain Mutants in Cancer Mitotic G2-G2/M phases Constitutive Signaling by NOTCH1 PEST Domain Mutants PPARA activates gene expression Cellular response to hypoxia Regulation of Hypoxia-inducible Factor (HIF) by oxygen Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer Attenuation phase G2/M Transition HATs acetylate histones RORA activates circadian gene expression HSF1-dependent transactivation TRAF3-dependent IRF activation pathway Signaling by NOTCH1 Transcriptional regulation of white adipocyte differentiation XAV939 inhibits tankyrase, stabilizing AXIN Pre-NOTCH Expression and Processing Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants FBXW7 Mutants and NOTCH1 in Cancer Innate Immune System Fatty acid, triacylglycerol, and ketone body metabolism Cytosolic sensors of pathogen-associated DNA Cellular response to heat stress REV-ERBA represses gene expression Cell Cycle, Mitotic RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways NOTCH1 Intracellular Domain Regulates Transcription TCF dependent signaling in response to WNT TRAF6 mediated IRF7 activation Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) Signaling by WNT in cancer BMAL1:CLOCK,NPAS2 activates circadian gene expression Polo-like kinase mediated events	Regulation of beta-cell development Regulation of gene expression in beta cells
EP300 and TCF7L2	E1A binding protein p300	transcription factor 7-like 2 (T-cell specific, HMG-box)	Signaling by NOTCH1 HD Domain Mutants in Cancer Metabolism of lipids and lipoproteins Signaling by Wnt NOTCH2 intracellular domain regulates transcription Regulation of gene expression by Hypoxia-inducible Factor Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Signaling by NOTCH2 Pre-NOTCH Transcription and Translation RNF mutants show enhanced WNT signaling and proliferation Signaling by NOTCH1 in Cancer Chromatin organization misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Signaling by NOTCH formation of the beta-catenin:TCF transactivating complex Factors involved in megakaryocyte development and platelet production Chromatin modifying enzymes LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Signaling by NOTCH1 PEST Domain Mutants in Cancer Mitotic G2-G2/M phases Constitutive Signaling by NOTCH1 PEST Domain Mutants PPARA activates gene expression Cellular response to hypoxia Regulation of Hypoxia-inducible Factor (HIF) by oxygen Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer Attenuation phase G2/M Transition HATs acetylate histones RORA activates circadian gene expression HSF1-dependent transactivation TRAF3-dependent IRF activation pathway Signaling by NOTCH1 Transcriptional regulation of white adipocyte differentiation XAV939 inhibits tankyrase, stabilizing AXIN Pre-NOTCH Expression and Processing Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants FBXW7 Mutants and NOTCH1 in Cancer Innate Immune System Fatty acid, triacylglycerol, and ketone body metabolism Cytosolic sensors of pathogen-associated DNA Cellular response to heat stress REV-ERBA represses gene expression Cell Cycle, Mitotic RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways NOTCH1 Intracellular Domain Regulates Transcription TCF dependent signaling in response to WNT TRAF6 mediated IRF7 activation Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) Signaling by WNT in cancer BMAL1:CLOCK,NPAS2 activates circadian gene expression Polo-like kinase mediated events	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated S37 mutants of beta-catenin aren't phosphorylated Peptide hormone metabolism Degradation of beta-catenin by the destruction complex S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN Incretin synthesis, secretion, and inactivation truncations of AMER1 destabilize the destruction complex misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
EP300 and PPARG	E1A binding protein p300	peroxisome proliferator-activated receptor gamma	Signaling by NOTCH1 HD Domain Mutants in Cancer Metabolism of lipids and lipoproteins Signaling by Wnt NOTCH2 intracellular domain regulates transcription Regulation of gene expression by Hypoxia-inducible Factor Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Signaling by NOTCH2 Pre-NOTCH Transcription and Translation RNF mutants show enhanced WNT signaling and proliferation Signaling by NOTCH1 in Cancer Chromatin organization misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Signaling by NOTCH formation of the beta-catenin:TCF transactivating complex Factors involved in megakaryocyte development and platelet production Chromatin modifying enzymes LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Signaling by NOTCH1 PEST Domain Mutants in Cancer Mitotic G2-G2/M phases Constitutive Signaling by NOTCH1 PEST Domain Mutants PPARA activates gene expression Cellular response to hypoxia Regulation of Hypoxia-inducible Factor (HIF) by oxygen Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer Attenuation phase G2/M Transition HATs acetylate histones RORA activates circadian gene expression HSF1-dependent transactivation TRAF3-dependent IRF activation pathway Signaling by NOTCH1 Transcriptional regulation of white adipocyte differentiation XAV939 inhibits tankyrase, stabilizing AXIN Pre-NOTCH Expression and Processing Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants FBXW7 Mutants and NOTCH1 in Cancer Innate Immune System Fatty acid, triacylglycerol, and ketone body metabolism Cytosolic sensors of pathogen-associated DNA Cellular response to heat stress REV-ERBA represses gene expression Cell Cycle, Mitotic RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways NOTCH1 Intracellular Domain Regulates Transcription TCF dependent signaling in response to WNT TRAF6 mediated IRF7 activation Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) Signaling by WNT in cancer BMAL1:CLOCK,NPAS2 activates circadian gene expression Polo-like kinase mediated events	PPARA activates gene expression Fatty acid, triacylglycerol, and ketone body metabolism Metabolism of lipids and lipoproteins Generic Transcription Pathway Transcriptional regulation of white adipocyte differentiation Nuclear Receptor transcription pathway Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)		Icosapent Troglitazone Mesalazine Indomethacin Rosiglitazone Nateglinide Sulfasalazine Repaglinide Telmisartan Balsalazide Ibuprofen Glipizide Pioglitazone Mitiglinide Bezafibrate (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID 3-(5-methoxy-1H-indol-3-yl)propanoic acid 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid 2-chloro-5-nitro-N-phenylbenzamide (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid ALEGLITAZAR
ERBB2 and ERBB3	erb-b2 receptor tyrosine kinase 2	erb-b2 receptor tyrosine kinase 3	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Axon guidance PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling Signaling by SCF-KIT SHC1 events in ERBB2 signaling Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Sema4D in semaphorin signaling Sema4D induced cell migration and growth-cone collapse Innate Immune System Signaling by PDGF Downregulation of ERBB2:ERBB3 signaling Signalling by NGF DAP12 interactions GAB1 signalosome Semaphorin interactions Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by FGFR Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System		Trastuzumab Lapatinib ado-trastuzumab emtansine Pertuzumab Afatinib
ERBB2 and SH2B3	erb-b2 receptor tyrosine kinase 2	SH2B adaptor protein 3	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Axon guidance PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling Signaling by SCF-KIT SHC1 events in ERBB2 signaling Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Sema4D in semaphorin signaling Sema4D induced cell migration and growth-cone collapse Innate Immune System Signaling by PDGF Downregulation of ERBB2:ERBB3 signaling Signalling by NGF DAP12 interactions GAB1 signalosome Semaphorin interactions Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by FGFR Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System	Signaling by SCF-KIT Regulation of KIT signaling Factors involved in megakaryocyte development and platelet production	Trastuzumab Lapatinib ado-trastuzumab emtansine Pertuzumab Afatinib
ERBB3 and JAK2	erb-b2 receptor tyrosine kinase 3	Janus kinase 2		Signaling by FGFR in disease Signaling by EGFRvIII in Cancer Interferon gamma signaling Toll Like Receptor TLR1:TLR2 Cascade Toll Like Receptor 5 (TLR5) Cascade Interleukin receptor SHC signaling Gastrin-CREB signalling pathway via PKC and MAPK MyD88 dependent cascade initiated on endosome SOS-mediated signalling Prolactin receptor signaling SHC-mediated signalling TRIF-mediated TLR3/TLR4 signaling ERK1 activation ERK1 activation GPCR downstream signaling Signaling by VEGF Downstream signal transduction Toll Like Receptor 3 (TLR3) Cascade Signalling to RAS Interleukin-2 signaling Platelet activation, signaling and aggregation Frs2-mediated activation Axon guidance IRS-mediated signalling Interleukin-6 signaling VEGFA-VEGFR2 Pathway Activated TLR4 signalling VEGFR2 mediated cell proliferation GRB2 events in ERBB2 signaling MyD88:Mal cascade initiated on plasma membrane TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation NCAM signaling for neurite out-growth RAF/MAP kinase cascade Signalling to p38 via RIT and RIN Innate Immune System Signaling by Insulin receptor Insulin receptor signalling cascade Interferon Signaling Signaling by Ligand-Responsive EGFR Variants in Cancer IRS-related events SHC-related events RMTs methylate histone arginines Signaling by FGFR ARMS-mediated activation Toll-Like Receptors Cascades Nuclear signaling by ERBB4 Toll Like Receptor 10 (TLR10) Cascade Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) Interleukin receptor SHC signaling GPVI-mediated activation cascade Signaling by GPCR FCERI mediated MAPK activation SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Toll Like Receptor 9 (TLR9) Cascade Signaling by PDGF DAP12 interactions G-protein beta:gamma signalling Chromatin organization GRB2 events in EGFR signaling SHC-related events triggered by IGF1R Factors involved in megakaryocyte development and platelet production Signaling by ERBB4 Toll Like Receptor 2 (TLR2) Cascade Signaling by ERBB2 Signaling by EGFR Signaling by Interleukins Chromatin modifying enzymes SHC1 events in ERBB4 signaling Toll Like Receptor 4 (TLR4) Cascade Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling Interleukin-3, 5 and GM-CSF signaling Growth hormone receptor signaling Signaling by Leptin Signalling to ERKs Prolonged ERK activation events ERK activation Toll Like Receptor 7/8 (TLR7/8) Cascade IGF1R signaling cascade Toll Like Receptor TLR6:TLR2 Cascade IRS-related events triggered by IGF1R MyD88 cascade initiated on plasma membrane ERK activation G beta:gamma signalling through PI3Kgamma Downstream signaling of activated FGFR Signalling by NGF SOS-mediated signalling MAP kinase activation in TLR cascade SHC-mediated signalling Cytokine Signaling in Immune system NGF signalling via TRKA from the plasma membrane MyD88-independent cascade Signaling by Overexpressed Wild-Type EGFR in Cancer ERK2 activation SHC1 events in EGFR signaling FRS2-mediated cascade IRS-mediated signalling ERK2 activation Regulation of IFNG signaling
ERBB3 and JAK3	erb-b2 receptor tyrosine kinase 3	Janus kinase 3		Signaling by GPCR G-protein beta:gamma signalling Cytokine Signaling in Immune system Signaling by Interleukins GPCR downstream signaling Interleukin receptor SHC signaling G beta:gamma signalling through PI3Kgamma Interleukin receptor SHC signaling Interleukin-7 signaling GPVI-mediated activation cascade Interleukin-2 signaling Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling
ERBB3 and PTK2B	erb-b2 receptor tyrosine kinase 3	protein tyrosine kinase 2 beta		Signaling by Interleukins Signaling by VEGF Cytokine Signaling in Immune system Interleukin-2 signaling Signal regulatory protein (SIRP) family interactions VEGFA-VEGFR2 Pathway		Leflunomide Genistein 4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide
ERBB3 and RIN1	erb-b2 receptor tyrosine kinase 3	Ras and Rab interactor 1
ERBB3 and PLCG1	erb-b2 receptor tyrosine kinase 3	phospholipase C, gamma 1		Signaling by the B Cell Receptor (BCR) Phospholipase C-mediated cascade Signaling by FGFR in disease FCERI mediated MAPK activation Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling DAP12 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Synthesis of IP3 and IP4 in the cytosol Signaling by FGFR1 mutants Role of phospholipids in phagocytosis Fcgamma receptor (FCGR) dependent phagocytosis Signaling by PDGF DAP12 interactions Inositol phosphate metabolism Antiviral mechanism by IFN-stimulated genes EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR TCR signaling Signaling by VEGF Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer Signaling by FGFR mutants Frs2-mediated activation Adaptive Immune System Signalling to ERKs Prolonged ERK activation events Axon guidance DAG and IP3 signaling VEGFA-VEGFR2 Pathway VEGFR2 mediated cell proliferation Downstream signaling of activated FGFR Netrin-1 signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Innate Immune System Signalling by NGF Generation of second messenger molecules ISG15 antiviral mechanism Interferon Signaling Cytokine Signaling in Immune system Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR PECAM1 interactions Cell surface interactions at the vascular wall Role of second messengers in netrin-1 signaling PLC-gamma1 signalling FCERI mediated Ca+2 mobilization Constitutive Signaling by EGFRvIII Signaling by FGFR1 fusion mutants
ERBB3 and NRG1	erb-b2 receptor tyrosine kinase 3	neuregulin 1		Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Signaling by EGFRvIII in Cancer Signaling by SCF-KIT SHC1 events in ERBB2 signaling Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signaling by PDGF Downregulation of ERBB2:ERBB3 signaling Signalling by NGF DAP12 interactions GAB1 signalosome Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by FGFR Signaling by ERBB2 Signaling by EGFR Nuclear signaling by ERBB4 SHC1 events in ERBB4 signaling Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System

Search Results for: Diabetes